Claire Phipps-Jones

IP litigation solicitor at Bristows LLP. Views expressed are my own.

[Aldi Stores UK @AldiUK]

A letter to @Channel4 #GBBO

[Claire Phipps-Jones @Claire_PJ]

This week's edition includes, among others, a UK decision on fuzzy boundaries!

[Bristows LLP @BristowsLawFirm]

The latest edition of our Irides Weekly Update is here. Taking its name from the plural of “iris” - a nod to the ability to see what’s happening around the world - the Weekly Update is a round-up of patent litigation news highlights from across the globe. https://t.co/oAhab3uluI

[Claire Phipps-Jones @Claire_PJ]

This week's Irides update: Grunenthal's TU patent invalid (UK); Astellas' mirabegron patent upheld (UK), new technical judges (UPC); reimbursement of opioids (DK); & the filing of divisionals during appeal (BR). https://t.co/8WgGXbSfIj #patentlitigation #upc #iridesweeklyupdate

[Claire Phipps-Jones @Claire_PJ]

This week's Irides update: the UK Court of Appeal's decision that Vernacare’s patent is invalid, the Australian Federal Court's invalidation of a CRISPR patent, the UPC'sfirst settlement and PTEs in Taiwan: https://t.co/DlVuTmMHbz #patentlitigation #upc #iridesweeklyupdate

[Claire Phipps-Jones @Claire_PJ]

The plot thickens... the preliminary opinion in T 0116/18 provides two possible interpretations of the decision in G 2/21: https://t.co/CJ6vLjafys (paragraphs 4.1-4.2)

[Claire Phipps-Jones @Claire_PJ]

My colleague Hugo Kent-Egan provides his view on Stembryos and the project launched to provide guidance on research using synthetic embryo models https://t.co/0GQJA9rMoV #embryos #stemcells #hfea #lifesciences #lifesciencesregulatory

[FierceBiotech @FierceBiotech]

Gilead's $225M bet on Arcellx’s CAR-T has hit turbulence. Months after Arcellx closed the deal, the FDA has put a pivotal trial of the anti-BCMA therapy on hold in response to a patient death. $GILD https://t.co/s3VHUGIKFD

[Claire Phipps-Jones @Claire_PJ]

Med-El v Advanced Bionics: inventive at the TBA, obvious in the UK. It is "often possible for two tribunals faced with a finely-balanced issue as to obviousness to reach opposing conclusions without either tribunal making an error". https://t.co/7k2pjkbkMS

[Claire Phipps-Jones @Claire_PJ]

By 31 May, the EPO received 800 requests for unitary effect, of which 600 will be published as granted in the next edition of the EP Bulletin. They also received 4,500 requests for deferred publication of the grant of the European patent. More at https://t.co/CWVhfMic5X

[Claire Phipps-Jones @Claire_PJ]

Current proposal for UPC Central division competencies: Milan - human necessities, Munich - chemistry and metallurgy and Paris - SPCs (based on patents from Sections A and C).  A decision may be made on 26 June. https://t.co/1Pio6lgzfV

[Claire Phipps-Jones @Claire_PJ]

BMS have sought permission to appeal in the apixaban case: https://t.co/P9ufhteyzn #lifesciences #patentlitigation

[Claire Phipps-Jones @Claire_PJ]

The first #upc cases have been filed. The first relates to the infringement of EP 3 375 337, entitled Sanitation Bath Tub Device! Perhaps more interestingly (at least to me), is the revocation action relating to EP 3 666 797 - an Amgen patent to antigen binding proteins to PCSK9.

[Claire Phipps-Jones @Claire_PJ]

The UPC has launched! Other last minute developments include that the DE and FR local divisions have added English as a language of proceedings, by my understanding leaving only the local division in Milan without English as an option.

[Claire Phipps-Jones @Claire_PJ]

Germany ratified... roll on a whole new litigation landscape! https://t.co/gkyp3niVKO

[Bristows LLP @BristowsLawFirm]

There is still time to register for our discussion on the evolving role of technology in women’s health. Join us on 18 January 2023, when our panel will consider, amongst other topics, the growth of the sector and its trends. Register your interest https://t.co/E9IFHqijYV

[Claire Phipps-Jones @Claire_PJ]

So it seems that AI cannot be an inventor of a patent in Australia after all - special leave to the High Court of Appeal has been denied in the DABUS case https://t.co/NDjWid7ZOW. Looking forward to the UK Supreme Court's view in March 2023!

[Claire Phipps-Jones @Claire_PJ]

Royalty Pharma Collection Trust v Boehringer Ingelheim GmbH: a costly misunderstanding and a lesson on the drafting of royalty clauses (via Passle) by @Ellen_Lambrix https://t.co/6R8FcN6KvJ #lifesciences #commercialandiptransactions #patentlitigation

[Claire Phipps-Jones @Claire_PJ]

My @BristowsLawFirm colleague @Ellen_Lambrix gives the lowdown on the BIA Bioscience Forum https://t.co/mswJwCXxuN #healthtech #artificialintelligence #lifesciences

[Claire Phipps-Jones @Claire_PJ]

Sorafenib - a case of obviousness with an interesting postscript (via Passle) by Claire Phipps-Jones https://t.co/SNmODmj2Au #patentlitigation #lifesciences

[Bristows LLP @BristowsLawFirm]

Teva v Bayer: Rob Burrows, Rachel Mumby and Bristows’ #patentlitigation team assisting Teva successfully revoke Bayer’s patent in a Patents Court decision handed down today. Here's the decision: https://t.co/S2fIQPIuBp